Between 5 and 27 March, 2021, seven occupants and one employee reported respiratory symptoms. this VOC, even in the elderly. Keywords:SARS-CoV-2, COVID-19, variant of concern, B.1.1.7, vaccine, outbreak == 1. Metixene hydrochloride hydrate Intro == Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) lineage B.1.1.7 (also known as the alpha variant) was first detected in the UK in late 2020. To day, this lineage has been reported in 163 countries [1]. In March 2021, B.1.1.7 became the dominant lineage in the UK, USA, Denmark, and Switzerland [2]. B.1.1.7 features 17 mutations and three deletions, including the N501Y substitution in the spike protein [2]. In some studies, this lineage has been associated with enhanced transmissibility, mortality, and more coronavirus disease 19 (COVID-19) hospitalizations compared to previously circulating SARS-CoV-2 lineages [2,3,4]. In addition, in vitro studies have shown a reduction of up to 11.4-fold in the neutralizing antibody capacity of plasma of vaccinated individuals (we.e., BNT162b2, mRNA-1273, and ChAdOx1) against wild-type B.1.1.7 isolates or pseudoviruses featuring the B.1.1.7 spike mutations, which suggests immune escape [5,6,7]. However, other studies show little or no difference in the neutralization antibody capacity of the plasma of vaccinated individuals against the B.1.1.7 variant compared to the original Wuhan or comparative strains [8,9]. In Brazil, the 1st cases caused by B.1.1.7 lineage were identified in So Paulo city in individuals who traveled from the UK in December 2020 [10]. The B.1.1.7 lineage has recently been detected in over 10 Brazilian claims resulting from multiples introductions [11]. In January 2021, the CoronaVac (Sinovac) and ChAdOx1 (Oxford-AstraZeneca) vaccines received Emergency Use Authorization from your Ministry of Health of Brazil. Both vaccines require two doses for completion of the vaccination series. The recommended interval between doses is 1428 days for CoronaVac and 90 days for the ChAdOx1 vaccine [12,13]. As of 27 August 2021, 47.5% (57.4 of 120.8 million) of individuals in Brazil experienced received a single dose of the ChAdOx1 vaccine, while 28.6% (34.6 of 120.8 million) were CoronaVac recipients. Ctsd On the other hand, 47.1% (25.6 of 54.4 million) of individuals were immunized with the complete series (i.e., two doses) of CoronaVac, and 41.2% (22.4 of 54.4 million) received two doses of the ChAdOx1 vaccine. To increase the number of individuals receiving at least a single dose of vaccine to avert COVID-19 severity and prevent mortality, it has been proposed to delay the second dose of the primary immunization series [14,15,16,17,18]. Several studies have investigated whether a single-dose regimen of the adenovirus-vectored vaccine or full immunization with an inactivated vaccine is sufficient to interrupt SARS-CoV-2 transmission [19,20,21]. This study, therefore, aimed to evaluate factors associated with two B.1.1.7 transmission clusters in the context of vaccination with ChAdOx1 and CoronaVac vaccines. == 2. Materials and Methods == == 2.1. Metixene hydrochloride hydrate Study Design, Metixene hydrochloride hydrate Participants, and Ethics == The SARS-CoV-2 outbreak investigations were performed in the collaboration with the Division of Health Monitoring of Campinas city inside a convent and a long-term care (LTC) facility in Campinas city, So Paulo State, Brazil. Inclusion criteria for our cohorts were individuals at least 18 years of age exposed to occupants infected with SARS-CoV-2 in these two locations in March 2021. Occupants and employees from both locations were included in the study. Nasopharyngeal and serum specimens were collected during a check out of health monitoring assistants between 24 and 29 March 2021, after a positive laboratory test inside a resident and the onset of symptoms in additional occupants. Clinical data were collected from electronic medical records, including age, sex, sign duration, the time between symptoms and collection, vaccination day, and hospitalization during the SARS-CoV-2 illness (Table S1). The collection of biological samples took place in the context of epidemiological investigation of the COVID-19 outbreak, including laboratory investigation of symptomatic instances and exposed contacts conducted from the municipal health surveillance division. == 2.2. RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction == Viral RNA was extracted from your nasopharyngeal swab samples using the Quick-DNA/RNA viral kit (Catalog quantity: D7021, Zymo Study, Irvine, CA, USA) according to the manufacturers instructions. The RNA from samples was tested by real-time quantitative polymerase chain reaction (RT-qPCR).